Open Access

Simvastatin delays castration‑resistant prostate cancer metastasis and androgen receptor antagonist resistance by regulating the expression of caveolin‑1

  • Authors:
    • Yingying Gao
    • Luo Li
    • Ting Li
    • Lei Ma
    • Mengjuan Yuan
    • Wei Sun
    • Hong Lin Cheng
    • Lingfang Niu
    • Zhongbo Du
    • Zhen Quan
    • Yanru Fan
    • Jiaxin Fan
    • Chunli Luo
    • Xiaohou Wu
  • View Affiliations

  • Published online on: April 5, 2019     https://doi.org/10.3892/ijo.2019.4774
  • Pages: 2054-2068
  • Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The failure of androgen deprivation therapy in prostate cancer treatment mainly results from drug resistance to androgen receptor antagonists. Although an aberrant caveolin‑1 (Cav‑1) expression has been reported in multiple tumor cell lines, it is unknown whether it is responsible for the progression of castration‑resistant prostate cancer (CRPC). Thus, the aim of the present study was to determine whether Cav‑1 can be used as a key molecule for the prevention and treatment of CRPC, and to explore its mechanism of action in CRPC. For this purpose, tissue and serum samples from patients with primary prostate cancer and CRPC were analyzed using immunohistochemistry and enzyme‑linked immunosorbent assay, which revealed that Cav‑1 was overexpressed in CRPC. Furthermore, Kaplan‑Meier survival analysis and univariate Cox proportional hazards regression analysis demonstrated that Cav‑1 expression in tumors was an independent risk factor for the occurrence of CRPC and was associated with a shorter recurrence‑free survival time in patients with CRPC. Receiver operating characteristic curves suggested that serum Cav‑1 could be used as a diagnostic biomarker for CRPC (area under the curve, 0.876) using a cut‑off value of 0.68 ng/ml (with a sensitivity of 82.1% and specificity of 80%). In addition, it was determined that Cav‑1 induced the invasion and migration of CRPC cells by the activation of the H‑Ras/phosphoinositide‑specific phospholipase Cε signaling cascade in the cell membrane caveolae. Importantly, simvastatin was able to augment the anticancer effects of androgen receptor antagonists by downregulating the expression of Cav‑1. Collectively, the findings of this study provide evidence that Cav‑1 is a promising predictive biomarker for CRPC and that lowering cholesterol levels with simvastatin or interfering with the expression of Cav‑1 may prove to be a useful strategy with which to prevent and/or treat CRPC.
View Figures
View References

Related Articles

Journal Cover

June 2019
Volume 54 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Gao, Y., Li, L., Li, T., Ma, L., Yuan, M., Sun, W. ... Wu, X. (2019). Simvastatin delays castration‑resistant prostate cancer metastasis and androgen receptor antagonist resistance by regulating the expression of caveolin‑1. International Journal of Oncology, 54, 2054-2068. https://doi.org/10.3892/ijo.2019.4774
MLA
Gao, Y., Li, L., Li, T., Ma, L., Yuan, M., Sun, W., Cheng, H. L., Niu, L., Du, Z., Quan, Z., Fan, Y., Fan, J., Luo, C., Wu, X."Simvastatin delays castration‑resistant prostate cancer metastasis and androgen receptor antagonist resistance by regulating the expression of caveolin‑1". International Journal of Oncology 54.6 (2019): 2054-2068.
Chicago
Gao, Y., Li, L., Li, T., Ma, L., Yuan, M., Sun, W., Cheng, H. L., Niu, L., Du, Z., Quan, Z., Fan, Y., Fan, J., Luo, C., Wu, X."Simvastatin delays castration‑resistant prostate cancer metastasis and androgen receptor antagonist resistance by regulating the expression of caveolin‑1". International Journal of Oncology 54, no. 6 (2019): 2054-2068. https://doi.org/10.3892/ijo.2019.4774